Diversity Management, News and Updates
Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen’s SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).
As the COVID-19 pandemic disproportionately impacts diverse communities, the need for greater diversity in vaccine trials is very evident. Black and Latinx people have been three times as likely as white people to be infected with the virus, and twice as likely to die, but they have historically made up…
Originally published on sanofi.com. Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19 Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to be available in the second…
Johnson & Johnson announced the launching of an eight-week-long educational live series hosted by producer and journalist Lisa Ling. The series will address the COVID-19 crisis and highlight global efforts to develop a vaccine and treatment options. Beginning April 14, every Tuesday, Johnson & Johnson will broadcast the series live…
Johnson & Johnson (A DiversityInc Hall of Fame Company) announced it has a lead candidate for a potential vaccine for COVID-19, the pandemic sweeping the world and killing thousands. “The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available…
Originally published on Sanofi.com. The U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application for Fluzone® High-Dose Quadrivalent (Influenza Vaccine) for use in adults 65 years of age and older. Fluzone® High-Dose (Influenza Vaccine) was approved by the FDA in 2009 as a trivalent influenza vaccine, including two…